Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.55 |
| ▸ | CCND1 | P24385 | 17/20 | 0.55 |
| ▸ | CCNE2 | O96020 | 11/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.55 |
| ▸ | CDK2 | P24941 | 11/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.55 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611027 | 1.00 | CDK4 (0.55) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5600433 | 0.92 | CRHR1 (0.57) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5599666 | 0.91 | CDK4 (0.54) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5600331 | 0.89 | CDK4 (0.53) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5600850 | 0.87 | CDK4 (0.51) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5599902 | 0.85 | CDK4 (0.52) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5599534 | 0.83 | CDK4 (0.53) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5599897 | 0.83 | CRHR1 (0.49) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7965911 | 0.82 | CRHR1 (0.63) | CDK4CCND1CCNE2CCNE1CDK2 | |
| Acetic Acid SCHEMBL7953282 | 0.81 | CDK4 (0.50) | CDK4CCND1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | disclosed |
| US-6218397-B1 | FOR THERAPY OF STRESS-RELATED ILLNESSES, SUCH AS STRESS-INDUCED DEPRESSION, ANXIETY, AND HEADACHE; ABDOMINAL BOWEL SYNDROME; INFLAMMATORY DISEASES; IMMUNE SUPPRESSION; ALZHEIMER'S DISEASE; GASTRONINTESTINAL DISEASES | PFIZER INC | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | CDK4 4323/4885CCND1 4856/4885CCNE2 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.